China's healthcare reforms are generating uncertainty for its domestic pharmaceutical market, writes Jon Zifferblatt.
Jon Zifferblatt
Advertisement
Articles by Jon Zifferblatt
Advertisement
Latest Updated Articles
Preparing For the New ChinaFebruary 23rd 2012
Advertisement
Advertisement
Trending on PharmExec
1
Trump Administration Preparing New Round of Medicaid Drug-Pricing Deals: Report
2
FDA Approves Lisraya for Adults with Dermatomyositis, Bixlenvo for Virologically Suppressed Adults with HIV, Mounjaro to Reduce MACE in Adults with Type 2 Diabetes
3
Pharmaceutical Executive Daily: DualityBio and Teva Strike Major Biopharma Deals
4
M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to Acquire Igalmi from BioXcel
5